Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (582)	4/19/2000 1:20:00 PM
From: gao seng	Respond to of 1834

Those are spectacular results. Thank you very much for posting that news. I would have missed it if I didn't have this thread bookmarked.

To: Jim Oravetz who wrote (582)	4/19/2000 11:16:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 1834

By any means this are far best results for second line MBT early clinical results (knowing to me), with good potential to move forward as first line therapy (at least for some cases if therapy resistance isn't issue). This results are from only single course therapy (four days), so I am very curious what will happen if that initial clinical response pts (>50% reduction) are retreated with IL-4 toxin. Also, some nice opportunity for other localized cancer type. I consider NBIX as primarily neuro-company, but have nothing to complain about this venture in cancer field. Miljenko